Synthesis of vildagliptin:research advances / 国际药学研究杂志

ABSTRACT

Vildagliptin is a kind of dipeptidyl peptidase Ⅳ(DPP-4) inhibitors. It is a new oral diabetes drug which is developed by Novartis. It reduces blood glucose levels by decreasing the concentration of glucagon,has remarkable advantages in drug safety and is widely used in the treatment of type 2 diabetes in clinic. In this paper,we summarize the synthetic methods of vildagliptin that have been reported in literature in recent years and their advantages and disadvantages.